JP2025507923A5 - - Google Patents

Info

Publication number
JP2025507923A5
JP2025507923A5 JP2024552265A JP2024552265A JP2025507923A5 JP 2025507923 A5 JP2025507923 A5 JP 2025507923A5 JP 2024552265 A JP2024552265 A JP 2024552265A JP 2024552265 A JP2024552265 A JP 2024552265A JP 2025507923 A5 JP2025507923 A5 JP 2025507923A5
Authority
JP
Japan
Prior art keywords
cancer
pclx
per day
hours
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2023/050281 external-priority patent/WO2023164776A1/en
Publication of JP2025507923A publication Critical patent/JP2025507923A/ja
Publication of JP2025507923A5 publication Critical patent/JP2025507923A5/ja
Pending legal-status Critical Current

Links

JP2024552265A 2022-03-03 2023-03-03 ヒトがんの処置における経口pclx-001 Pending JP2025507923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
US63/316,153 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (2)

Publication Number Publication Date
JP2025507923A JP2025507923A (ja) 2025-03-21
JP2025507923A5 true JP2025507923A5 (cg-RX-API-DMAC7.html) 2026-03-12

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552265A Pending JP2025507923A (ja) 2022-03-03 2023-03-03 ヒトがんの処置における経口pclx-001

Country Status (10)

Country Link
US (1) US20250161299A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486344A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507923A (cg-RX-API-DMAC7.html)
KR (1) KR20240155234A (cg-RX-API-DMAC7.html)
CN (1) CN118829428A (cg-RX-API-DMAC7.html)
AU (1) AU2023228703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244234A1 (cg-RX-API-DMAC7.html)
IL (1) IL314984A (cg-RX-API-DMAC7.html)
MX (1) MX2024010584A (cg-RX-API-DMAC7.html)
WO (1) WO2023164776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102496892B1 (ko) * 2012-10-30 2023-02-06 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
EP3325662B1 (en) * 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Similar Documents

Publication Publication Date Title
NZ590431A (en) Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
JP2023515235A5 (cg-RX-API-DMAC7.html)
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2022533578A5 (cg-RX-API-DMAC7.html)
RU2013134359A (ru) Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
JP2024506612A5 (cg-RX-API-DMAC7.html)
JP2021513536A5 (cg-RX-API-DMAC7.html)
WO2005084712A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
JP2016522202A5 (cg-RX-API-DMAC7.html)
JP2017526662A5 (cg-RX-API-DMAC7.html)
JP2023542093A5 (cg-RX-API-DMAC7.html)
CN104582708A (zh) 用于治疗小细胞肺癌的苯并二氮*类
CN111936143A (zh) 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
GEAP202416383A (en) Use of medicament in treatment of tumor disease
JP2021105005A5 (cg-RX-API-DMAC7.html)
Bender et al. Novel inhibitor of Notch signaling for the treatment of cancer.
Campana et al. The value of electrochemotherapy in the treatment of peristomal tumors
JP2014005265A5 (cg-RX-API-DMAC7.html)
EP1568383A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
JP2023515687A5 (cg-RX-API-DMAC7.html)
Zhang et al. Discovery of novel small molecules targeting TGF-β signaling for the treatment of non-small cell lung cancer
NO20084635L (no) Fosfor inneholdende forbindelser inkludert trifenylmetylfosfonat estere for behandlingen av melanoma og andre kreftformer
JP2020520385A5 (cg-RX-API-DMAC7.html)
JP2022526525A5 (cg-RX-API-DMAC7.html)